Less itch and more sleep with baricitinib
|
Rapid itch reduction was seen as early as one week in this phase 2 data studying Baricitinib for the treatment of Moderate to Severe Atopic Dermatitis (AD). Baricitinib is a once-daily oral Janus kinase (JAK) 1 and 2 inhibitor. The JAK’s will soon be coming to the world of Dermatology specifically in Psoriasis, Psoriatic Arthritis and Atopic Dermatitis. |